You just read:

CAS Group Announces Glass Lewis Recommendation That Aviragen Stockholders Vote AGAINST Merger and Emphasizes Value of Teslexivir (BTA074) Program

News provided by

Digirad Corporation

Jan 31, 2018, 09:00 ET